Key Highlights

  • Fiscal third quarter net loss was $7.7 million, against $1.3 million a year earlier, and the company has no revenue.
  • Cash was $1.97 million on July 31, and the quarterly report states substantial doubt about continuing as a going concern.
  • Warrant exercises on September 4 brought in about $1.75 million of gross proceeds, and 28,206,698 shares were outstanding.
  • The company completed a preclinical collagen study and targets a 510(k) submission for a wound-care device in early 2027.

Conexeu Sciences (NASDAQ:CNXU) shares were trading near their 52-week low at USD 3.20 on October 19, 2026, up 4.41%. The regenerative medicine company listed on Nasdaq on May 21, 2026, has no commercial sales and carries going concern language in its latest quarterly report. A September 10 filing also reports new share and warrant issuances.

Fiscal third quarter loss, cash and going concern doubt

Conexeu reported unaudited results for the quarter ended July 31, 2026, the third quarter of its fiscal year ending October 31. It has reported no revenue. Operating expenses were $7.7 million against $1.3 million a year earlier, and the net loss was $7.7 million, or $0.29 per share, compared with $1.3 million, or $0.09. For the nine months, the net loss was $11.7 million, or $0.52 per share, and the accumulated deficit reached $16.3 million.

Cash and cash equivalents were $1.97 million at July 31, down from $4.81 million at October 31, 2025, with a further $238,208 of restricted cash. Operating activities used $10.1 million over the nine months, while financing activities contributed $7.5 million. Total liabilities were $1.3 million, no loan was outstanding, and shareholders' equity was $5.85 million.

The filing states that accumulated losses and continued losses raise substantial doubt about the company's ability to continue as a going concern. Continuing depends on obtaining debt or equity financing, and the filing says no assurance can be given that financing will be available.

Share issuance and warrant exercises

Shares outstanding rose to 28,206,698 on September 10 from 20,916,173 on April 30. A Form 8-K filed on September 10 reported 1,448,368 unregistered common shares and 202,500 warrants issued between June 18 and September 4 under consulting and director agreements and warrant exercises.

The largest item was a September 4 exercise of warrants under an incentive program, covering 762,608 shares at $2.30 per share for about $1.75 million of gross proceeds, which the company said it would use for working capital. That cash arrived after the July 31 balance sheet date. A June 18 issuance under the same program brought in about $162,000.

Related-party disclosures show one director's warrants vesting on the May 21 Nasdaq listing, and a June 15 notice set annual cash fees and restricted share units for directors.

CXU platform and the road to a 510(k) submission

Conexeu describes itself as a pre-commercial company developing cellular therapies for skin restoration in wound care and aesthetics. CXU, built on a patent-protected collagen platform, is its only device candidate, and the company states that CXU and its devices are investigational and not FDA cleared for any use.

On July 7, it said it had completed the 12-month, animal-model P.R.O.O.F. phase of its preclinical program. It reported meeting objectives in a small-volume cheek model and a large-volume model, and performance benchmarks for injectability and volumizing. Detailed findings have not been disclosed, and the company plans peer-reviewed publication.

The lead candidate, Ten-Minute Tissue, is a thermosensitive extracellular matrix that stays fluid at room temperature and gels at body temperature in about ten minutes.

Outlook: wound-care filing and funding needs

Conexeu targeted a predicate-based 510(k) submission for a wound-care device in the first quarter of 2027, subject to testing, manufacturing and documentation, and cited a targeted 90-day FDA review. The quarterly report puts the expected timing of a 510(k) submission, which is also a warrant vesting milestone, at March 31, 2027, versus June 30, 2026 previously. Wound care would be the first commercial indication, with aesthetics planned afterward.

The company lists limited operating history, a single device candidate, the need for additional financing, practitioner adoption, product liability exposure and dependence on key personnel among its risks.